[ad_1]
The American company Moderna reported that the effectiveness of its vaccine against COVID-19 was 94.1% and against the severe form of coronavirus infection, 100%. 30 thousand people attended the tests.
Efficacy of the mRNA-1273 coronavirus vaccine from an American company Modern against the severe form of COVID-19 it was 100%. This was announced on November 30 by the company’s website.
The effectiveness of the COVID-19 vaccine was 94.1%. The drug as a whole is still well tolerated, no serious safety issues have been identified, according to the report.
30,000 people participated in the vaccine trials, of which 196 volunteers became ill with COVID-19: 185 received a placebo, 11, the vaccine. Based on these data, the scientists concluded that the vaccine was effective in 94.1% of cases.
30 participants in the trials contracted severe COVID-19, all of whom received a placebo. All those who were vaccinated mRNA-1273, did not get sick, noted in the company statement.
During the vaccine trials, one person died while receiving a placebo.
The third phase of trials of Moderna’s mRNA-1273 coronavirus vaccine showed an efficacy of 94.5%.
Moderna announced the successful completion of the second phase of clinical trials in mid-July. 45 people between 18 and 55 years old attended. The third and final phase of testing for mRNA-1273 began on July 27.
An outbreak of coronavirus infection began in late 2019 in China. On March 11, 2020, the World Health Organization declared the spread of the coronavirus a pandemic.
According to the US Johns Hopkins University, as of November 30, more than 62.8 million people fell ill with COVID-19 in the world. 1.46 million people died from this disease and 40.2 million recovered.
As of November 12, according to the World Health Organization, 48 COVID-19 vaccine manufacturers worldwide are candidates for clinical evaluation of the vaccine produced. 164 companies are conducting preclinical trials.
